Skip to content

Study · Not a test of the peptide alone · 2018

7 results

Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: A single center experience.

Zhou L, Pan LC, Zheng YG, Du GS, Fu XQ, Zhu ZD, Song JY, Liu ZJ, Su XZ, Chen W, Zheng DH, Suo LL, Yang SZ

Oncology letters27 Jul 2018Cited by 15 (Europe PMC)

PMID30214575 (opens in a new tab)PMCIDPMC6126158 (opens in a new tab)DOI10.3892/ol.2018.9226 (opens in a new tab)PepBankPUB-30214575
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In liver transplant recipients with advanced HCC, a regimen of sirolimus, thymalfasin and huaier granules gave longer recurrence times than tacrolimus-based therapy.

    In plain wordsIn liver transplant patients with advanced liver cancer, a regimen of sirolimus, thymalfasin and huaier granules delayed recurrence more than tacrolimus-based therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTime to HCC recurrence
    Study

    n = 36

    Comparator
    Tacrolimus-based therapy
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The SRL+ group had significantly longer recurrence times (P=0.008) and survival times (P<0.0001) (OS, 1-year: 100%, 3-year: 94.4%, 5-year: 77.8%; DFS, 1-year: 88.9%, 3-year: 55.6%, 5-year: 50.0%).
    1 context sentence
    Summary · context
    The present study retrospectively analyzed data from 36 non-University of California at San Francisco criteria-eligible patients with advanced HCC who underwent LT, and then treated them with sirolimus (SRL)-based therapy with thymalfasin and huaier granules (SRL+, n=18), or with tacrolimus-based th…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In liver transplant recipients with advanced HCC, a regimen of sirolimus, thymalfasin and huaier granules gave longer survival times than tacrolimus-based therapy.

    In plain wordsIn liver transplant patients with advanced liver cancer, a regimen of sirolimus, thymalfasin and huaier granules gave longer survival than tacrolimus-based therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseOverall survival
    Study

    n = 36

    Comparator
    Tacrolimus-based therapy
    Outcome group
    Mortality · Cancer

    Measurements

    5-year OS
    77.8%
    SRL+ group

    Source sentences

    Summary
    The SRL+ group had significantly longer recurrence times (P=0.008) and survival times (P<0.0001) (OS, 1-year: 100%, 3-year: 94.4%, 5-year: 77.8%; DFS, 1-year: 88.9%, 3-year: 55.6%, 5-year: 50.0%).
    1 context sentence
    Summary · context
    The present study retrospectively analyzed data from 36 non-University of California at San Francisco criteria-eligible patients with advanced HCC who underwent LT, and then treated them with sirolimus (SRL)-based therapy with thymalfasin and huaier granules (SRL+, n=18), or with tacrolimus-based th…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In liver transplant recipients with advanced HCC, serum AFP was lower with the regimen of sirolimus, thymalfasin and huaier granules than before transplant and than in controls.

    In plain wordsIn liver transplant patients with liver cancer, a regimen of sirolimus, thymalfasin and huaier granules lowered a tumor marker more than tacrolimus-based therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum alpha-fetoprotein
    Study

    n = 36

    Comparator
    Tacrolimus-based therapy
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Furthermore, compared with pre-LT values and the control group, the SRL+ group had significantly lower serum α-fetoprotein (AFP) levels (both P+ Treg lymphocytes (P<0.001) during the first year.
    1 context sentence
    Summary · context
    The present study retrospectively analyzed data from 36 non-University of California at San Francisco criteria-eligible patients with advanced HCC who underwent LT, and then treated them with sirolimus (SRL)-based therapy with thymalfasin and huaier granules (SRL+, n=18), or with tacrolimus-based th…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneObservational studyMechanism

    In liver transplant recipients with advanced HCC, the percentage of FoxP3+ Treg lymphocytes was lower with the regimen of sirolimus, thymalfasin and huaier granules than before transplant and than in controls.

    In plain wordsIn liver transplant patients, a regimen of sirolimus, thymalfasin and huaier granules lowered regulatory T cells more than tacrolimus-based therapy.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseFoxP3+ Treg lymphocyte percentage
    Study

    n = 36

    Comparator
    Tacrolimus-based therapy
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Furthermore, compared with pre-LT values and the control group, the SRL+ group had significantly lower serum α-fetoprotein (AFP) levels (both P+ Treg lymphocytes (P<0.001) during the first year.
    1 context sentence
    Summary · context
    The present study retrospectively analyzed data from 36 non-University of California at San Francisco criteria-eligible patients with advanced HCC who underwent LT, and then treated them with sirolimus (SRL)-based therapy with thymalfasin and huaier granules (SRL+, n=18), or with tacrolimus-based th…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In liver transplant recipients with advanced HCC, the regimen of sirolimus, thymalfasin and huaier granules reported 5-year disease-free survival of 50.0%.

    In plain wordsIn liver transplant patients with advanced liver cancer, half of those on sirolimus, thymalfasin and huaier granules were free of disease at 5 years.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableDisease-free survival
    Study

    n = 18

    Outcome group
    Tumor growth · Cancer

    Measurements

    5-year DFS
    50%
    SRL+ group

    Source sentences

    Summary
    The SRL+ group had significantly longer recurrence times (P=0.008) and survival times (P<0.0001) (OS, 1-year: 100%, 3-year: 94.4%, 5-year: 77.8%; DFS, 1-year: 88.9%, 3-year: 55.6%, 5-year: 50.0%).
    1 context sentence
    Summary · context
    The present study retrospectively analyzed data from 36 non-University of California at San Francisco criteria-eligible patients with advanced HCC who underwent LT, and then treated them with sirolimus (SRL)-based therapy with thymalfasin and huaier granules (SRL+, n=18), or with tacrolimus-based th…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneObservational studyMechanism

    In liver transplant recipients, FoxP3+/CD8+ Treg percentages fell after transplant in the group on sirolimus, thymalfasin and huaier granules.

    In plain wordsIn liver transplant patients on a regimen of sirolimus, thymalfasin and huaier granules, one type of regulatory T cell fell after transplant.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseFoxP3+/CD8+ Treg percentage after transplant
    Study

    n = 18

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In the SRL+ group, FoxP3+/cluster of differentiation (CD)8+ Treg lymphocyte percentages decreased significantly following LT (P+/CD3+ T-cells significantly increased (P<0.001).
    1 context sentence
    Summary · context
    The present study retrospectively analyzed data from 36 non-University of California at San Francisco criteria-eligible patients with advanced HCC who underwent LT, and then treated them with sirolimus (SRL)-based therapy with thymalfasin and huaier granules (SRL+, n=18), or with tacrolimus-based th…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07HumanNot a test of Thymosin alpha-1 aloneObservational studyMechanism

    In liver transplant recipients, CD8+/CD3+ T-cells rose after transplant in the group on sirolimus, thymalfasin and huaier granules.

    In plain wordsIn liver transplant patients on a regimen of sirolimus, thymalfasin and huaier granules, CD8 T cells rose after transplant.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD8+/CD3+ T-cell percentage after transplant
    Study

    n = 18

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In the SRL+ group, FoxP3+/cluster of differentiation (CD)8+ Treg lymphocyte percentages decreased significantly following LT (P+/CD3+ T-cells significantly increased (P<0.001).
    1 context sentence
    Summary · context
    The present study retrospectively analyzed data from 36 non-University of California at San Francisco criteria-eligible patients with advanced HCC who underwent LT, and then treated them with sirolimus (SRL)-based therapy with thymalfasin and huaier granules (SRL+, n=18), or with tacrolimus-based th…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.